Skip to main content
Top
Published in: European Journal of Nutrition 8/2009

01-12-2009 | Original Contribution

Advanced glycation end products strongly activate platelets

Authors: Thomas Gawlowski, Bernd Stratmann, Ruth Ruetter, Christina E. Buenting, Barbara Menart, Jürgen Weiss, Helen Vlassara, Theodor Koschinsky, Diethelm Tschoepe

Published in: European Journal of Nutrition | Issue 8/2009

Login to get access

Abstract

Background

Diabetes mellitus is characterized by hyperglycemia that plays an important role in the pathogenesis of diabetic complications including cardiovascular diseases. Moreover, hyperglycemia induces increased generation of advanced glycation end products (AGEs). The activation of platelets is associated with the development of cardiovascular diseases.

Aim of the study

The question whether AGEs acutely induce platelet activation as a response to exogenous stimulus is addressed.

Materials and methods

The effect of AGEs derived from food and human serum being purified by lysozyme affinity chromatography was examined by incubating in vitro freshly isolated blood platelets from fasted subjects at various concentrations and different time points. Platelet activation, determined as expression of surface markers CD62 and CD63, and the presence of the receptor for AGEs (RAGE) in platelet membranes was measured by flow cytometric analysis using specific antibodies.

Results

Incubation with food-derived as well as serum-derived AGEs stimulated significantly the expression of CD62 up to 7.1-fold and CD63 up to 2.2-fold at the platelet surface membrane as a function of concentration and time. Incubation with thrombin or AGEs significantly increased RAGE expression twofold at the platelet surface membrane.

Conclusions

The increase in surface activation marker and RAGE expression in platelets, resulting from concentrations of AGEs that occur in vivo after a meal or a drink as a source of exogenous AGEs, points to signaling mechanisms for food AGEs that could favor the precipitation of acute postprandial ischemic events.
Literature
1.
go back to reference Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ (2005) Assay of advanced glycation end products in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 49:691–699CrossRef Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ (2005) Assay of advanced glycation end products in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 49:691–699CrossRef
2.
go back to reference Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Muller M, Nawroth PP (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262–2271 Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Muller M, Nawroth PP (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262–2271
3.
go back to reference Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A et al (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699–1712 Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A et al (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699–1712
4.
go back to reference Buenting CE, Koschinsky T, Schwippert B, Ruetter R, Weiss J, Roesen P, Tschoepe D (2001) Food advanced glycation end products induce activation of platelets by increasing expression of receptors for AGE. Diabetologia 44:A33 Buenting CE, Koschinsky T, Schwippert B, Ruetter R, Weiss J, Roesen P, Tschoepe D (2001) Food advanced glycation end products induce activation of platelets by increasing expression of receptors for AGE. Diabetologia 44:A33
5.
go back to reference Cai W, He JC, Zhu L, Lu C, Vlassara H (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 103:13801–13806CrossRef Cai W, He JC, Zhu L, Lu C, Vlassara H (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 103:13801–13806CrossRef
6.
go back to reference Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM (2004) Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 65:1664–1675CrossRef Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM (2004) Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 65:1664–1675CrossRef
7.
go back to reference Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115:3378–3384CrossRef Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115:3378–3384CrossRef
8.
go back to reference Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104:1287–1291CrossRef Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104:1287–1291CrossRef
9.
go back to reference Harmon JT, Jamieson GA (1986) The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem 261:13224–13229 Harmon JT, Jamieson GA (1986) The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem 261:13224–13229
10.
go back to reference Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879–887CrossRef Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879–887CrossRef
11.
go back to reference Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474–6479CrossRef Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474–6479CrossRef
12.
go back to reference Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810–17814CrossRef Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810–17814CrossRef
13.
go back to reference Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P (2000) Platelet-leukocyte crosstalk in whole blood. Arterioscler Thromb Vasc Biol 20:2702–2708 Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P (2000) Platelet-leukocyte crosstalk in whole blood. Arterioscler Thromb Vasc Biol 20:2702–2708
14.
go back to reference Li YM, Tan AX, Vlassara H (1995) Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1:1057–1061CrossRef Li YM, Tan AX, Vlassara H (1995) Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1:1057–1061CrossRef
15.
go back to reference Lupu C, Calb M, Ionescu M, Lupu F (1993) Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost 70:579–583 Lupu C, Calb M, Ionescu M, Lupu F (1993) Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost 70:579–583
16.
go back to reference Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133–5138 Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133–5138
17.
go back to reference Mauron J (1981) The Maillard reaction in food; a critical review from the nutritional standpoint. Prog Food Nutr Sci 5:5–35 Mauron J (1981) The Maillard reaction in food; a critical review from the nutritional standpoint. Prog Food Nutr Sci 5:5–35
18.
go back to reference Mitsuhashi T, Li YM, Fishbane S, Vlassara H (1997) Depletion of reactive advanced glycation end products from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100:847–854CrossRef Mitsuhashi T, Li YM, Fishbane S, Vlassara H (1997) Depletion of reactive advanced glycation end products from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100:847–854CrossRef
19.
go back to reference Mitsuhashi T, Vlassara H, Founds HW, Li YM (1997) Standardizing the immunological measurement of advanced glycation end products using normal human serum. J Immunol Methods 207:79–88CrossRef Mitsuhashi T, Vlassara H, Founds HW, Li YM (1997) Standardizing the immunological measurement of advanced glycation end products using normal human serum. J Immunol Methods 207:79–88CrossRef
20.
go back to reference Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2007) Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85:1236–1243 Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2007) Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85:1236–1243
21.
go back to reference Nicholl ID, Bucala R (1998) Advanced glycation end products and cigarette smoking. Cell Mol Biol (Noisy-le-grand) 44:1025–1033 Nicholl ID, Bucala R (1998) Advanced glycation end products and cigarette smoking. Cell Mol Biol (Noisy-le-grand) 44:1025–1033
22.
go back to reference O’Brien J, Morrissey PA (1989) Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 28:211–248CrossRef O’Brien J, Morrissey PA (1989) Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 28:211–248CrossRef
23.
go back to reference Okumura T, Hasitz M, Jamieson GA (1978) Platelet glycocalicin. Interaction with thrombin and role as thrombin receptor of the platelet surface. J Biol Chem 253:3435–3443 Okumura T, Hasitz M, Jamieson GA (1978) Platelet glycocalicin. Interaction with thrombin and role as thrombin receptor of the platelet surface. J Biol Chem 253:3435–3443
24.
go back to reference Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239 Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239
25.
go back to reference Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, Stefan N, Humpert P, Fritsche A, Stumvoll M, Schleicher E, Haring HU, Nawroth PP, Bierhaus A (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621–633CrossRef Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, Stefan N, Humpert P, Fritsche A, Stumvoll M, Schleicher E, Haring HU, Nawroth PP, Bierhaus A (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621–633CrossRef
26.
go back to reference Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521–1528 Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521–1528
27.
go back to reference Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064–2071CrossRef Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064–2071CrossRef
28.
go back to reference Stratmann B, Tschoepe D (2005) Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2:16–23CrossRef Stratmann B, Tschoepe D (2005) Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2:16–23CrossRef
29.
go back to reference Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H (2005) Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 1043:461–466CrossRef Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H (2005) Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 1043:461–466CrossRef
30.
go back to reference Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30:2579–2582CrossRef Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30:2579–2582CrossRef
31.
go back to reference Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1:634–646 Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1:634–646
32.
go back to reference Vlassara H, Palace MR (2003) Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70:232–241 Vlassara H, Palace MR (2003) Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70:232–241
33.
go back to reference Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D’Agati V, Schmidt AM (2003) Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14:1383–1395CrossRef Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D’Agati V, Schmidt AM (2003) Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14:1383–1395CrossRef
34.
go back to reference Willoughby S, Holmes A, Loscalzo J (2002) Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 1:273–288CrossRef Willoughby S, Holmes A, Loscalzo J (2002) Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 1:273–288CrossRef
35.
go back to reference Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889–9897 Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889–9897
36.
go back to reference Yngen M, Ostenson CG, Hjemdahl P, Wallen NH (2006) Meal-induced platelet activation in type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 23:134–140CrossRef Yngen M, Ostenson CG, Hjemdahl P, Wallen NH (2006) Meal-induced platelet activation in type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 23:134–140CrossRef
Metadata
Title
Advanced glycation end products strongly activate platelets
Authors
Thomas Gawlowski
Bernd Stratmann
Ruth Ruetter
Christina E. Buenting
Barbara Menart
Jürgen Weiss
Helen Vlassara
Theodor Koschinsky
Diethelm Tschoepe
Publication date
01-12-2009
Publisher
D. Steinkopff-Verlag
Published in
European Journal of Nutrition / Issue 8/2009
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-009-0038-6

Other articles of this Issue 8/2009

European Journal of Nutrition 8/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.